Objective:To study the effect of danhong injection combined with sodium ozagrel on serum IL-8, TNF-α, VEGF, TBIL and NSE in old patients with acute cerebral infarction.Methods:A total of 100 old patients with acute c...Objective:To study the effect of danhong injection combined with sodium ozagrel on serum IL-8, TNF-α, VEGF, TBIL and NSE in old patients with acute cerebral infarction.Methods:A total of 100 old patients with acute cerebral infarction in our hospital from August 2014 to December 2016 were enrolled in this study. The subjects were divided into the control group (n=50) and the treatment group (n=50) randomly. The control group was treated with sodium ozagrel, the treatment group was treated with danhong injection combined with sodium ozagrel, and both the two groups were treated for 14 days. The serum IL-8, TNF-α, VEGF, TBIL and NSE of the two groups before and after treatment were compared.Results:There were no significantly differences of the serum IL-8, TNF-α, VEGF, TBIL and NSE of the two groups before treatment. The serum IL-8, TNF-α, NSE levels of the two groups after treatment were significantly lower than before treatment, the serum VEGF, TBIL levels of the two groups after treatment were significantly higher than before treatment, and that of the treatment group after treatment were significantly better than the control group.Conclusion:Danhong injection combined with sodium ozagrel can significantly reduce the serum IL-8, TNF-α, NSE levels, improve the serum VEGF, TBIL levels, and reduce inflammation, promote the nerve functional recovery of the old patients with acute cerebral infarction, and it was worthy clinical application.展开更多
目的:应用Meta分析的方法评价舒血宁注射液单用与联合奥扎格雷钠治疗急性脑梗死的临床疗效和安全性。方法:计算机检索多个中外文献数据库,检索时限均为各数据库建库至2016年10月,查找舒血宁注射液单用与联合奥扎格雷钠治疗急性脑梗死的...目的:应用Meta分析的方法评价舒血宁注射液单用与联合奥扎格雷钠治疗急性脑梗死的临床疗效和安全性。方法:计算机检索多个中外文献数据库,检索时限均为各数据库建库至2016年10月,查找舒血宁注射液单用与联合奥扎格雷钠治疗急性脑梗死的随机对照试验相关文献,按Cochrane手册对所纳入的文献进行质量评价,并应用Rev Man 5.3软件进行Meta分析。结果:最终纳入13项随机对照试验,合计1244例患者。Meta分析结果显示,舒血宁注射液联合奥扎格雷钠治疗急性脑梗死的临床疗效比值比(OR)合并值为4.51(95%可信区间为3.16~6.44);神经功能缺损评分疗效加权均数差(WMD)合并值为-0.91(95%可信区间为-5.55~3.72)。结论:舒血宁注射液联合奥扎格雷钠治疗急性脑梗死的临床疗效显著优于单用舒血宁注射液,且未见明显不良反应。但由于现有的研究方法学质量均较低,上述结论仍需要更多大样本、高质量的随机对照试验予以验证。展开更多
文摘Objective:To study the effect of danhong injection combined with sodium ozagrel on serum IL-8, TNF-α, VEGF, TBIL and NSE in old patients with acute cerebral infarction.Methods:A total of 100 old patients with acute cerebral infarction in our hospital from August 2014 to December 2016 were enrolled in this study. The subjects were divided into the control group (n=50) and the treatment group (n=50) randomly. The control group was treated with sodium ozagrel, the treatment group was treated with danhong injection combined with sodium ozagrel, and both the two groups were treated for 14 days. The serum IL-8, TNF-α, VEGF, TBIL and NSE of the two groups before and after treatment were compared.Results:There were no significantly differences of the serum IL-8, TNF-α, VEGF, TBIL and NSE of the two groups before treatment. The serum IL-8, TNF-α, NSE levels of the two groups after treatment were significantly lower than before treatment, the serum VEGF, TBIL levels of the two groups after treatment were significantly higher than before treatment, and that of the treatment group after treatment were significantly better than the control group.Conclusion:Danhong injection combined with sodium ozagrel can significantly reduce the serum IL-8, TNF-α, NSE levels, improve the serum VEGF, TBIL levels, and reduce inflammation, promote the nerve functional recovery of the old patients with acute cerebral infarction, and it was worthy clinical application.
文摘目的:应用Meta分析的方法评价舒血宁注射液单用与联合奥扎格雷钠治疗急性脑梗死的临床疗效和安全性。方法:计算机检索多个中外文献数据库,检索时限均为各数据库建库至2016年10月,查找舒血宁注射液单用与联合奥扎格雷钠治疗急性脑梗死的随机对照试验相关文献,按Cochrane手册对所纳入的文献进行质量评价,并应用Rev Man 5.3软件进行Meta分析。结果:最终纳入13项随机对照试验,合计1244例患者。Meta分析结果显示,舒血宁注射液联合奥扎格雷钠治疗急性脑梗死的临床疗效比值比(OR)合并值为4.51(95%可信区间为3.16~6.44);神经功能缺损评分疗效加权均数差(WMD)合并值为-0.91(95%可信区间为-5.55~3.72)。结论:舒血宁注射液联合奥扎格雷钠治疗急性脑梗死的临床疗效显著优于单用舒血宁注射液,且未见明显不良反应。但由于现有的研究方法学质量均较低,上述结论仍需要更多大样本、高质量的随机对照试验予以验证。